CRYBB3

Summary

CRYBB3 (crystallin beta B3, HGNC:2400) is a protein-coding gene on chromosome 22q11.23, encoding Beta-crystallin B3 (P26998). Crystallins are the dominant structural components of the vertebrate eye lens.

Crystallins are separated into two classes: taxon-specific, or enzyme, and ubiquitous. The latter class constitutes the major proteins of vertebrate eye lens and maintains the transparency and refractive index of the lens. Since lens central fiber cells lose their nuclei during development, these crystallins are made and then retained throughout life, making them extremely stable proteins. Mammalian lens crystallins are divided into alpha, beta, and gamma families; beta and gamma crystallins are also considered as a superfamily. Alpha and beta families are further divided into acidic and basic groups. Seven protein regions exist in crystallins: four homologous motifs, a connecting peptide, and N- and C-terminal extensions. Beta-crystallins, the most heterogeneous, differ by the presence of the C-terminal extension (present in the basic group, none in the acidic group). Beta-crystallins form aggregates of different sizes and are able to self-associate to form dimers or to form heterodimers with other beta-crystallins. This gene, a beta basic group member, is part of a gene cluster with beta-A4, beta-B1, and beta-B2. Mutations in this gene result in cataract congenital nuclear autosomal recessive type 2.

Source: NCBI Gene 1417 — RefSeq curated summary.

At a glance

• Gene–disease (curated): cataract 22 multiple types (Definitive, GenCC) — +3 more curated relationships
• Clinical variants (ClinVar): 134 total — 3 pathogenic, 4 likely-pathogenic
• Phenotypes (HPO): 6
• MANE Select transcript: NM_004076

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:2400
Approved symbol	CRYBB3
Name	crystallin beta B3
Location	22q11.23
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000100053
Ensembl biotype	protein_coding
OMIM	123630
Entrez	1417

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 2 protein_coding

ENST00000215855, ENST00000404334

RefSeq mRNA: 1 — MANE Select: NM_004076 NM_004076

CCDS: CCDS13830

Canonical transcript exons

ENST00000215855 — 6 exons

Exon	Start	End
ENSE00000651767	25201377	25201471
ENSE00000651768	25202674	25202792
ENSE00000651769	25203763	25203895
ENSE00000651770	25205220	25205362
ENSE00001719172	25207047	25207359
ENSE00001919673	25199858	25199909

Expression profiles

Bgee: expression breadth ubiquitous, 145 present calls, max score 82.07.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.3888 / max 341.7285, expressed in 40 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
191464	0.3888	40

Top tissues by expression

257 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	82.07	gold quality
buccal mucosa cell	CL:0002336	76.59	gold quality
mucosa of transverse colon	UBERON:0004991	74.15	gold quality
tendon of biceps brachii	UBERON:0008188	73.30	gold quality
lower esophagus mucosa	UBERON:0035834	72.93	gold quality
right lobe of liver	UBERON:0001114	72.91	gold quality
lens of camera-type eye	UBERON:0000965	72.56	silver quality
endometrium epithelium	UBERON:0004811	69.99	gold quality
biceps brachii	UBERON:0001507	67.73	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	67.41	gold quality
secondary oocyte	CL:0000655	66.88	gold quality
parotid gland	UBERON:0001831	66.80	gold quality
inferior olivary complex	UBERON:0002127	66.54	gold quality
left lobe of thyroid gland	UBERON:0001120	65.57	gold quality
right lobe of thyroid gland	UBERON:0001119	65.30	gold quality
dorsal motor nucleus of vagus nerve	UBERON:0002870	65.06	gold quality
nephron tubule	UBERON:0001231	65.00	gold quality
deltoid	UBERON:0001476	64.91	gold quality
thyroid gland	UBERON:0002046	64.79	gold quality
gingival epithelium	UBERON:0001949	64.73	gold quality
myocardium	UBERON:0002349	64.62	gold quality
medial globus pallidus	UBERON:0002477	63.59	gold quality
gingiva	UBERON:0001828	63.36	gold quality
esophagus mucosa	UBERON:0002469	63.24	gold quality
heart right ventricle	UBERON:0002080	63.06	gold quality
adult mammalian kidney	UBERON:0000082	62.84	gold quality
globus pallidus	UBERON:0001875	62.42	gold quality
liver	UBERON:0002107	62.40	gold quality
middle temporal gyrus	UBERON:0002771	62.39	gold quality
cartilage tissue	UBERON:0002418	62.28	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	1.78

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

3 targeting CRYBB3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-877-3P	99.09	68.10	1637
HSA-MIR-4468	98.01	66.85	1187
HSA-MIR-7113-5P	97.88	67.33	1735

Literature-anchored findings (GeneRIF, showing 3)

• For the first time, a mutation in CRYBB3 is reported in two consanguineous Pakistani families with autosomal recessive congenital cataracts. (PMID:15914629)
• The first pregnancy was terminated in week 22. Copy number variation analysis revealed, in both the aborted fetus and the mother, a 495 kb duplication at 22q11.23 encompassing CRYBB3 and CRYBB2 (PMID:27256633)
• a common ancestral mutation in CRYBB3 associated with autosomal recessive congenital cataracts identified in four familial cases of Pakistani origin, is reported. (PMID:27326458)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	crybb3	ENSDARG00000041301
mus_musculus	Crybb3	ENSMUSG00000029352
rattus_norvegicus	Crybb3	ENSRNOG00000047673

Paralogs (14): CRYBG3 (ENSG00000080200), CRYBB1 (ENSG00000100122), CRYBA1 (ENSG00000108255), CRYBG1 (ENSG00000112297), CRYGD (ENSG00000118231), CRYGN (ENSG00000127377), CRYGC (ENSG00000163254), CRYBA2 (ENSG00000163499), CRYGA (ENSG00000168582), CRYBG2 (ENSG00000176092), CRYGB (ENSG00000182187), CRYBA4 (ENSG00000196431), CRYGS (ENSG00000213139), CRYBB2 (ENSG00000244752)

Protein

Protein identifiers

Beta-crystallin B3 — P26998 (reviewed: P26998)

Alternative names: Beta-B3 crystallin

All UniProt accessions (2): P26998, B1AHR5

UniProt curated annotations — full annotation on UniProt →

Function. Crystallins are the dominant structural components of the vertebrate eye lens.

Subunit / interactions. Homo/heterodimer, or complexes of higher-order. The structure of beta-crystallin oligomers seems to be stabilized through interactions between the N-terminal arms.

Disease relevance. Cataract 22, multiple types (CTRCT22) [MIM:609741] An opacification of the crystalline lens of the eye that frequently results in visual impairment or blindness. Opacities vary in morphology, are often confined to a portion of the lens, and may be static or progressive. In general, the more posteriorly located and dense an opacity, the greater the impact on visual function. CTRCT22 includes nuclear cataract among others. Nuclear cataracts affect the central nucleus of the eye, and are often not highly visually significant. The density of the opacities varies greatly from fine dots to a dense, white and chalk-like, central cataract. The condition is usually bilateral. Nuclear cataracts are often combined with opacified cortical fibers encircling the nuclear opacity, which are referred to as cortical riders. The disease is caused by variants affecting the gene represented in this entry.

Domain organisation. Has a two-domain beta-structure, folded into four very similar Greek key motifs.

Similarity. Belongs to the beta/gamma-crystallin family.

RefSeq proteins (1): NP_004067* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001064	Beta/gamma_crystallin	Domain
IPR011024	G_crystallin-like	Homologous_superfamily
IPR050252	Beta/Gamma-Crystallin	Family

Pfam: PF00030

UniProt features (42 total): strand 15, sequence variant 6, helix 5, domain 4, region of interest 3, chain 2, modified residue 2, sequence conflict 2, turn 2, initiator methionine 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
3QK3	X-RAY DIFFRACTION	1.95

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P26998-F1	87.52	0.78

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 1, 2

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 52 (showing top): GOBP_SENSORY_PERCEPTION_OF_LIGHT_STIMULUS, GOBP_SENSORY_PERCEPTION, GOBP_SENSORY_ORGAN_DEVELOPMENT, MORF_WNT1, MCCABE_HOXC6_TARGETS_CANCER_UP, GOBP_LENS_DEVELOPMENT_IN_CAMERA_TYPE_EYE, GOMF_STRUCTURAL_CONSTITUENT_OF_EYE_LENS, YOSHIMURA_MAPK8_TARGETS_UP, GOMF_STRUCTURAL_MOLECULE_ACTIVITY, MIKKELSEN_MEF_HCP_WITH_H3_UNMETHYLATED, MARTENS_TRETINOIN_RESPONSE_UP, KIM_BIPOLAR_DISORDER_OLIGODENDROCYTE_DENSITY_CORR_DN, GOBP_SENSORY_SYSTEM_DEVELOPMENT, SHEDDEN_LUNG_CANCER_GOOD_SURVIVAL_A12, ZWANG_TRANSIENTLY_UP_BY_2ND_EGF_PULSE_ONLY

GO Biological Process (2): lens development in camera-type eye (GO:0002088), visual perception (GO:0007601)

GO Molecular Function (2): structural constituent of eye lens (GO:0005212), protein binding (GO:0005515)

GO Cellular Component (0):

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
camera-type eye development	1
anatomical structure development	1
sensory perception of light stimulus	1
structural molecule activity	1
binding	1

Protein interactions and networks

STRING

1613 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CRYBB3	CRYAA	P02489	870
CRYBB3	GCNT2	Q8N0V5	815
CRYBB3	CRYAB	P02511	814
CRYBB3	GJA8	P48165	784
CRYBB3	BFSP1	Q12934	780
CRYBB3	GJA3	Q9Y6H8	774
CRYBB3	BFSP2	Q13515	760
CRYBB3	TRNT1	Q96Q11	756
CRYBB3	LIM2	P55344	727
CRYBB3	HSF4	Q9ULV5	699
CRYBB3	TMEM114	B3SHH9	664
CRYBB3	PITX3	O75364	611
CRYBB3	TDRD7	Q8NHU6	593
CRYBB3	CHMP4B	Q9H444	591
CRYBB3	FOXE3	Q13461	575

IntAct

42 interactions, top by confidence:

A	B	Type	Score
CRYBA1	CRYBB3	psi-mi:“MI:0915”(physical association)	0.720
CRYBB3	CRYBA1	psi-mi:“MI:0915”(physical association)	0.720
MAJIN	CRYBB3	psi-mi:“MI:0914”(association)	0.560
CRYBB3	DOK6	psi-mi:“MI:0915”(physical association)	0.560
CASP6	CRYBB3	psi-mi:“MI:0915”(physical association)	0.560
CRYAA	CRYBB3	psi-mi:“MI:0915”(physical association)	0.560
DYNC1H1	CRYBB3	psi-mi:“MI:0915”(physical association)	0.560
CRYBB3		psi-mi:“MI:0915”(physical association)	0.560
LAMP2	CRYBB3	psi-mi:“MI:0915”(physical association)	0.560
PRPF40A	CRYBB3	psi-mi:“MI:0915”(physical association)	0.560
MAJIN	CRYBB3	psi-mi:“MI:0915”(physical association)	0.560
CSN2	CRYBB3	psi-mi:“MI:0914”(association)	0.530
GRB2	CRYBB3	psi-mi:“MI:0915”(physical association)	0.400
CRYBB3	TAB1	psi-mi:“MI:0915”(physical association)	0.400
CRYBB3	CRYBA1	psi-mi:“MI:0915”(physical association)	0.370

BioGRID (63): CRYBB3 (Two-hybrid), CRYBB3 (Affinity Capture-MS), TAB1 (Affinity Capture-MS), CRYBA1 (Two-hybrid), DOK6 (Two-hybrid), HIST1H1E (Affinity Capture-MS), CRYBB3 (Affinity Capture-MS), CRYBB3 (Affinity Capture-MS), CRYBB3 (Affinity Capture-MS), PRG3 (Affinity Capture-MS), NLRP2 (Affinity Capture-MS), ANKHD1 (Affinity Capture-MS), PHLDB3 (Affinity Capture-MS), APAF1 (Affinity Capture-MS), RGPD5 (Affinity Capture-MS)

ESM2 similar proteins: A2IBH5, A2IBY7, A3KGF7, A4D1Z8, A8MX76, E7F9T0, F6Q2R9, O88644, O89040, P02522, P02523, P02524, P07318, P07530, P13943, P19141, P26998, P43320, P49221, P50281, P53672, P53674, P53690, P55165, P62696, P62697, P62698, Q007T1, Q05714, Q10739, Q2LEC2, Q3UW68, Q4V8Q1, Q5BK10, Q5EF38, Q5RES1, Q6J756, Q6MZZ7, Q91318, Q91320

Diamond homologs: A2IBH5, A2IBY7, A2ICR5, A3RLD7, A3RLD8, A3RLE1, A3RLE2, A4L9I8, A4L9I9, A4QNB6, D3ZEG1, F6Q2R9, O35486, P02522, P02523, P02524, P02525, P02526, P02527, P02528, P02529, P02530, P02531, P04342, P04344, P04345, P05813, P06504, P07315, P07316, P07317, P07318, P07320, P07530, P08209, P0C5E9, P10042, P10043, P10065, P10066

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
CRYBB2	“up-regulates activity”	CRYBB3	binding

Disease & clinical

Clinical variants and AI predictions

ClinVar

134 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	3
Likely pathogenic	4
Uncertain significance	81
Likely benign	13
Benign	13

Top pathogenic / likely-pathogenic (7)

Variant ID	HGVS	Classification
143233	NM_004076.5(CRYBB3):c.581T>A (p.Val194Glu)	Pathogenic
16948	NM_004076.5(CRYBB3):c.493G>C (p.Gly165Arg)	Pathogenic
1704644	NM_004076.5(CRYBB3):c.467G>A (p.Gly156Glu)	Pathogenic
2009486	NM_004076.5(CRYBB3):c.392T>G (p.Ile131Arg)	Likely pathogenic
217351	NM_004076.5(CRYBB3):c.634T>C (p.Ter212Arg)	Likely pathogenic
3901180	NM_004076.5(CRYBB3):c.466G>C (p.Gly156Arg)	Likely pathogenic
4456860	NM_004076.5(CRYBB3):c.470+1G>A	Likely pathogenic

SpliceAI

1166 predictions. Top by Δscore:

Variant	Effect	Δscore
22:25205358:GGGAC:G	donor_gain	1.0000
22:25205359:GGAC:G	donor_gain	1.0000
22:25205359:GGACG:G	donor_gain	1.0000
22:25205360:G:GT	donor_gain	1.0000
22:25205360:G:T	donor_gain	1.0000
22:25205360:GAC:G	donor_gain	1.0000
22:25205363:G:GG	donor_gain	1.0000
22:25205369:G:T	donor_gain	1.0000
22:25201367:T:TA	acceptor_gain	0.9900
22:25202788:GGGCC:G	donor_gain	0.9900
22:25202789:GGCC:G	donor_gain	0.9900
22:25202789:GGCCG:G	donor_gain	0.9900
22:25202790:GCC:G	donor_gain	0.9900
22:25202790:GCCG:G	donor_gain	0.9900
22:25202793:G:GG	donor_gain	0.9900
22:25203896:G:GG	donor_gain	0.9900
22:25205148:C:CA	acceptor_gain	0.9900
22:25205149:G:A	acceptor_gain	0.9900
22:25205152:ATCT:A	acceptor_gain	0.9900
22:25205153:T:G	acceptor_gain	0.9900
22:25205155:T:TA	acceptor_gain	0.9900
22:25205218:AGG:A	acceptor_loss	0.9900
22:25205219:GGATA:G	acceptor_gain	0.9900
22:25205335:TGGC:T	donor_gain	0.9900
22:25205336:GGCG:G	donor_gain	0.9900
22:25205338:C:T	donor_gain	0.9900
22:25205360:GACGT:G	donor_loss	0.9900
22:25205361:AC:A	donor_gain	0.9900
22:25205361:ACGT:A	donor_loss	0.9900
22:25205362:CGTA:C	donor_loss	0.9900

AlphaMissense

1401 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
22:25207048:T:A	W158R	0.996
22:25207048:T:C	W158R	0.996
22:25205340:A:C	S150R	0.994
22:25205342:T:A	S150R	0.994
22:25205342:T:G	S150R	0.994
22:25203842:T:A	W92R	0.992
22:25203842:T:C	W92R	0.992
22:25205322:T:C	F144L	0.992
22:25205324:C:A	F144L	0.992
22:25205324:C:G	F144L	0.992
22:25205341:G:T	S150I	0.992
22:25205359:G:A	G156E	0.992
22:25203764:T:A	W66R	0.991
22:25203764:T:C	W66R	0.991
22:25203807:T:A	V80D	0.991
22:25205323:T:C	F144S	0.991
22:25207050:G:C	W158C	0.991
22:25207050:G:T	W158C	0.991
22:25203773:T:C	F69L	0.990
22:25203775:T:A	F69L	0.990
22:25203775:T:G	F69L	0.990
22:25205304:A:C	S138R	0.990
22:25205306:C:A	S138R	0.990
22:25205306:C:G	S138R	0.990
22:25205344:T:A	V151D	0.990
22:25207055:G:A	G160D	0.990
22:25207079:G:T	G168V	0.990
22:25202770:T:C	S58P	0.989
22:25205358:G:T	G156W	0.989
22:25207079:G:A	G168E	0.989

dbSNP variants (sampled 300 via entrez): RS1000167961 (22:25204906 C>T), RS1000427188 (22:25199489 A>G), RS1000475372 (22:25199098 T>G), RS1000686992 (22:25205140 A>G), RS1000762776 (22:25199301 T>C), RS1000826307 (22:25198776 A>G), RS1001288390 (22:25205989 T>C), RS1001574200 (22:25205748 G>A,C,T), RS1001587841 (22:25198387 A>C), RS1003438117 (22:25202727 C>T), RS1003438249 (22:25202298 G>A), RS1004245075 (22:25206603 G>A), RS1004361269 (22:25206788 A>G), RS1004383237 (22:25201702 G>A), RS1005498357 (22:25202483 G>A)

Disease associations

OMIM: gene MIM:123630 | disease phenotypes: MIM:609741, MIM:116200

GenCC curated gene-disease

Disease	Classification	Inheritance
cataract 22 multiple types	Definitive	Autosomal recessive
early-onset anterior polar cataract	Supportive	Autosomal dominant
early-onset nuclear cataract	Supportive	Autosomal dominant
early-onset non-syndromic cataract	Limited	Autosomal dominant

Mondo (6): cataract 22 multiple types (MONDO:0012336), cataract (MONDO:0005129), microphthalmia (MONDO:0021129), early-onset non-syndromic cataract (MONDO:0011060), early-onset anterior polar cataract (MONDO:0020373), early-onset nuclear cataract (MONDO:0020376)

Orphanet (1): Early onset non-syndromic cataract (Orphanet:91492)

HPO phenotypes

6 total (8 of 6 shown, HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0000007	Autosomal recessive inheritance
HP:0000501	Glaucoma
HP:0000519	Developmental cataract
HP:0003577	Congenital onset
HP:0100018	Nuclear cataract
HP:0000518	Cataract
HP:0000568	Microphthalmia

GWAS associations

0 associations (top):

MeSH disease descriptors (4)

Descriptor	Name	Tree numbers
D002386	Cataract	C11.510.245
D008850	Microphthalmos	C11.250.566; C16.131.384.666
C563333	Cataract, Age-Related Nuclear (supp.)
C565725	Cataract, Congenital Nuclear, Autosomal Recessive 2 (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

19 total (human), top 19 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Air Pollutants	increases expression, decreases expression, increases abundance	3
Smoke	decreases expression, increases abundance, increases expression	2
Particulate Matter	decreases expression, increases abundance, increases expression	2
aristolochic acid I	increases expression	1
sodium arsenite	decreases expression	1
perfluorooctanoic acid	affects cotreatment, decreases expression	1
perfluorooctane sulfonic acid	affects cotreatment, decreases expression	1
perfluorohexanesulfonic acid	affects cotreatment, decreases expression	1
Fulvestrant	decreases methylation	1
Ethanol	decreases expression	1
Arsenic	affects methylation	1
Carbon Tetrachloride	decreases expression	1
Coal	increases expression, increases abundance	1
Dichlorodiphenyl Dichloroethylene	decreases expression	1
Diethylhexyl Phthalate	increases expression	1
Endosulfan	increases expression	1
Silicon Dioxide	increases expression	1
Tobacco Smoke Pollution	decreases expression	1
Valproic Acid	increases methylation	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00273221	PHASE4	UNKNOWN	Combined Phacotube vs Phacotrabeculectomy:A Randomized Controlled Trial
NCT00312299	PHASE4	COMPLETED	Posterior Capsule Opacification Study
NCT00345046	PHASE4	COMPLETED	A Comparison of Three Different Formulations of Prednisolone Acetate 1%
NCT00347243	PHASE4	COMPLETED	Wavefront Analisys and Contrast Sensitivity of Spherical and Aspherical Intraocular Lenses
NCT00347503	PHASE4	COMPLETED	Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients
NCT00348244	PHASE4	COMPLETED	Ketorolac vs. Steroid in the Prevention of CME
NCT00348270	PHASE4	COMPLETED	Comparison of the Quality of Vision Provided by AMO Tecnis Z9000 and Alcon Laboratories MA60 Acrysof Posterior Chamber Intraocular Lenses
NCT00348582	PHASE4	COMPLETED	Acular LS vs. Nevanac in Post op Inflammation Following Cataract Surgery
NCT00348621	PHASE4	COMPLETED	A Study of Interventions to Reduce Disability From Visual Loss in Nursing Home Residents
NCT00349583	PHASE4	COMPLETED	Efficacy of Topical Cyclosporine Versus Tears for Improving Visual Outcomes Following Multifocal IOL Implantation
NCT00355446	PHASE4	COMPLETED	Bioavailability of Bimatoprost Ophthalmic Solution in Human Aqueous.
NCT00386438	PHASE4	COMPLETED	Efficacy of Honan Balloon in Intraocular Pressure Reduction Before Phacoemulsification
NCT00392275	PHASE4	COMPLETED	Penetrance of Third Generation Fluoroquinolones in Eyes With Functioning Filtering Blebs
NCT00428363	PHASE4	COMPLETED	Effect of Optic Edge Design in a Silicone Intraocular Lens on Posterior Capsule Opacification
NCT00449267	PHASE4	COMPLETED	Aurolab Hydrophobic Foldable Intraocular Lens Study
NCT00459303	PHASE4	COMPLETED	Comparison of Functional Vision Provided by AMO Tecnis Z9000 and Alcon SA60AT Acrysof
NCT00469690	PHASE4	COMPLETED	Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients: Trough Drug Effects
NCT00576485	PHASE4	COMPLETED	Spherical Aberration and Contrast Sensitivity in IOLs
NCT00612729	PHASE4	COMPLETED	Light Filters in Intraocular Lenses (IOLs) and Its Influence on Colour and Contrast Vision.
NCT00612781	PHASE4	COMPLETED	Yellow Versus White Study
NCT00630019	PHASE4	COMPLETED	Ocular Tissue Levels of 1.5% Levofloxacin Ophthalmic Solution Compared to an Active Comparator
NCT00673803	PHASE4	COMPLETED	Influence of Two Different Preloaded Intraocular Lens (IOLs) on Posterior Capsule Opacification
NCT00684138	PHASE4	COMPLETED	ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power Intraocular Lens (IOL)
NCT00698724	PHASE4	COMPLETED	Comparing Optical Coherence Tomography (OCT) and Visual Acuity Outcomes in Subjects Undergoing Cataract Surgery, Who Receive Xibrom Ophthalmic Solution and Standard Presurgical Care vs. Xibrom Ophthalmic Solution Plus Prednisolone Acetate 1% and Standard Presurgical Care
NCT00710905	PHASE4	TERMINATED	Visual Function With Contralateral AcrySof® ReSTOR® Aspheric SN6AD1 and SN6AD3
NCT00710931	PHASE4	COMPLETED	Visual Function With Bilateral AcrySof® ReSTOR® Aspheric SN6AD1
NCT00711347	PHASE4	COMPLETED	Intraoperative Floppy Iris Syndrome
NCT00712244	PHASE4	COMPLETED	DisCoVisc Versus DuoVisc, Healon5 and AmVisc Plus
NCT00717080	PHASE4	COMPLETED	The Role of Capsular Tension Ring (CTR) in Anterior Capsular Contraction
NCT00719732	PHASE4	COMPLETED	Visual Function After Implantation of Bilateral AcrySof ReSTOR Aspheric +3
NCT00721253	PHASE4	COMPLETED	Visual Outcomes of Subjects Bilaterally Implanted With ReSTOR Aspheric +4 vs. Tecnis or Acri.LISA
NCT00731640	PHASE4	COMPLETED	Contralateral ReSTOR / Monofocal or Phakic Eye
NCT00732030	PHASE4	COMPLETED	Low Cylinder Toric
NCT00758199	PHASE4	COMPLETED	Determination of Optimum Duration of Treatment With Bromfenac (Xibrom) Eyedrops Following Cataract Surgery
NCT00760058	PHASE4	WITHDRAWN	Visual Outcome and Visual Quality After Bilateral Implantation of the AcrySof® IQ IOL Compared to MI60® and Tecnis® IOL
NCT00760487	PHASE4	COMPLETED	Visual Function After Implantation of Bilateral AcrySof® Toric Natural Intraocular Lens
NCT00761488	PHASE4	WITHDRAWN	Recommendations for Monitoring Clinical Experience Following Implantation of the AcrySof® Toric
NCT00763360	PHASE4	COMPLETED	To Compare the Ability of DiscoVisc® OVD to Protect the Corneal Endothelium and Maintain Anterior Chamber Space With Healon® and Amvisc® PLUS During Cataract Surgery.
NCT00786370	PHASE4	COMPLETED	Dexmedetomidine vs. Propofol for Cataract Surgery
NCT00786565	PHASE4	COMPLETED	Clinical Evaluation of a New Aspheric Intraocular Lens.